ASCO 2022 | How can we improve responses to immunotherapy in patients with bladder cancer?

Joaquim Bellmunt, MD, PhD, Harvard Medical School and Dana-Farber Cancer Institute, Boston, MA, discusses how we can improve responses to immunotherapy (IO) in bladder cancer. More clinical trials are needed to improve patient response to IO. Currently there are trials involving the investigation of combining IO’s as well as the modification of the microbiome to improve IO efficacy. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.